MetLife Investment Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-21,600
| Closed | -$400K | – | 2894 |
|
|
2023
Q3 | $400K | Buy |
21,600
+8,853
| +69% | +$100K | ﹤0.01% | 1770 |
|
|
2023
Q2 | $141K | Hold |
12,747
| – | – | ﹤0.01% | 2487 |
|
|
2023
Q1 | $171K | Hold |
12,747
| – | – | ﹤0.01% | 2310 |
|
|
2022
Q4 | $158K | Hold |
12,747
| – | – | ﹤0.01% | 2392 |
|
|
2022
Q3 | $178K | Sell |
12,747
-3,729
| -23% | -$60K | ﹤0.01% | 2370 |
|
|
2022
Q2 | $228K | Hold |
16,476
| – | – | ﹤0.01% | 2224 |
|
|
2022
Q1 | $268K | Buy |
16,476
+5,261
| +47% | +$82.4K | ﹤0.01% | 2165 |
|
|
2021
Q4 | $183K | Hold |
11,215
| – | – | ﹤0.01% | 2101 |
|
|
2021
Q3 | $167K | Hold |
11,215
| – | – | ﹤0.01% | 2201 |
|
|
2021
Q2 | $224K | Hold |
11,215
| – | – | ﹤0.01% | 2091 |
|
|
2021
Q1 | $259K | Hold |
11,215
| – | – | ﹤0.01% | 1899 |
|
|
2020
Q4 | $277K | Hold |
11,215
| – | – | ﹤0.01% | 1809 |
|
|
2020
Q3 | $465K | Hold |
11,215
| – | – | 0.01% | 1402 |
|
|
2020
Q2 | $537K | Hold |
11,215
| – | – | 0.01% | 1337 |
|
|
2020
Q1 | $706K | Hold |
11,215
| – | – | 0.01% | 1049 |
|
|
2019
Q4 | $1.39M | Hold |
11,215
| – | – | 0.01% | 949 |
|
|
2019
Q3 | $744K | Hold |
11,215
| – | – | 0.01% | 1204 |
|
|
2019
Q2 | $892K | Buy |
11,215
+1,537
| +16% | +$138K | 0.01% | 1163 |
|
|
2019
Q1 | $1.08M | Hold |
9,678
| – | – | 0.01% | 1047 |
|
|
2018
Q4 | $975K | Buy |
9,678
+453
| +5% | +$47K | 0.01% | 1025 |
|
|
2018
Q3 | $1.17M | Sell |
9,225
-928
| -9% | -$98.2K | 0.01% | 1061 |
|
|
2018
Q2 | $852K | Buy |
+10,153
| New | +$743K | 0.01% | 1096 |
|
MetLife Investment Management's ICPT Position: Q4 2023 in Review
MetLife Investment Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 21,600 shares — an estimated $400K sold.
MetLife Investment Management first reported a position in ICPT in Q2 2018 and held it in 22 quarters. The position peaked at $1.39M in Q4 2019. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- MetLife Investment Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- MetLife Investment Management sold 21,600 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $400K.
- MetLife Investment Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2018 and held it in 22 quarters.
- MetLife Investment Management's Intercept Pharmaceuticals, Inc. position peaked at $1.39M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on MetLife Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.